Arcus Biosciences, Inc. — Director's Dealing 2020

Jun 8, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Arcus Biosciences, Inc. (RCUS)
CIK: 0001724521
Period of Report: 2020-06-04

Reporting Person: KANEKO YASUNORI (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-06-04	Common Stock	A	3000	$0.00	Acquired	3000	Direct
2020-06-05	Common Stock	M	35000	$7.99	Acquired	38000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-04	Stock Option (Right to Buy)	$30.05	A	14000	Acquired	2030-06-03	Common Stock (14000)	Direct
2020-06-05	Stock Option (Rights to Buy)	$7.99	M	35000	Disposed	2029-06-05	Common Stock (35000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	505050	Indirect
Common Stock	252524	Indirect
Common Stock	96948	Indirect

Footnotes

F1: Represents the grant of restricted stock units that vest 100% on the earlier of June 4, 2021 or the next annual meeting of the stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control

F2: Represents the exercise of options to purchase common stock by the reporting person. No shares were sold by the reporting person, and the shares received upon the exercise of such options are subject to a lock-up agreement with the underwriters for the Company's recent public offering.

F3: The option will vest in full on the earlier of (i) 12 months following the date of grant or (ii) the date of the next annual stockholder meeting following the grant. The option becomes fully vested and exercisable in the event the Company is subject to a change in control.